三生国健股价跌5.16%，交银施罗德基金旗下1只基金重仓，持有158.43万股浮亏损失464.2万元

Core Viewpoint - Sangfor Technologies experienced a 5.16% decline in stock price, closing at 53.89 CNY per share, with a trading volume of 2.27 billion CNY and a turnover rate of 0.66%, resulting in a total market capitalization of 33.239 billion CNY [1] Company Overview - Sangfor Technologies was established on January 25, 2002, and went public on July 22, 2020. The company is located in the China (Shanghai) Free Trade Zone [1] - The main business activities of Sangfor Technologies include the research, production, and sales of antibody drugs. The revenue composition is as follows: 75.24% from product sales, 15.37% from commissioned processing services, 7.94% from licensing services, and 1.44% from leasing services [1] Fund Holdings - According to data from the top ten holdings of funds, one fund under Jiao Yin Schroder has a significant position in Sangfor Technologies. The Jiao Yin Medical Innovation Stock A (004075) reduced its holdings by 786,100 shares in the second quarter, retaining 1,584,300 shares, which accounts for 3.31% of the fund's net value, ranking as the tenth largest holding [2] - The Jiao Yin Medical Innovation Stock A (004075) was established on March 23, 2017, with a current scale of 2.5 billion CNY. Year-to-date returns are 42.95%, ranking 1149 out of 4221 in its category; the one-year return is 30.68%, ranking 1720 out of 3848; and since inception, the return is 206.28% [2] - The fund manager of Jiao Yin Medical Innovation Stock A is Lou Huiyuan, who has been in the position for 7 years and 30 days. The total asset size of the fund is 4.04 billion CNY, with the best return during the tenure being 167.44% and the worst being -15.88% [2]